Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice pop today. =) Looks pretty due for a jump to the .20's
As predicted, opioids are a no go now investing wise.
What caused the spike from .10 to .40 last year? Looking at the market cap here and the chart it seems like this is due for a nice pop this year. Whether or not it's sustained is a different topic.
We "bounced" a whole .003; my suggestion is to not track the minute by minute price movements of a penny stock. There's no point.
I like your feelings. Let's have them come true.
Currently around an $85 million market cap and could do around that amount in revenue next fiscal year.
A bargain here.
***** Within the next 7 weeks, ALL of the following will happen: *****
1. Elite Pharmaceuticals And SunGen Pharma File ANDA For An Antibiotic. (Product #4)
2. Elite Pharmaceuticals Enters into Strategic Marketing Alliance with ---------- For Codeine And Acetaminophen Combo. (Tylenol® with Codeine)
3. Elite Pharmaceuticals Announces Commercial Launch Of Generic Adderall XR With Marketing Partner Lannett Company.
4. Elite Pharmaceuticals And SunGen Pharma Receive FDA Approval For An Antibiotic. (Product #3 - Minor Amendment)
5. Elite Pharmaceuticals, Inc. Receives FDA Approval for Loxapine Capsules. (May not receive a PR for this. Will be updated on the CC.)
6. Elite Pharmaceuticals, Inc. Reports Record Revenues For The Third Quarter Of Fiscal Year 2020.
(Profitability also expected due to $600,000 sale of Norco and Percocet, increased profit splits from Adderall IR, increased manufacturing revenues for Adderall IR due to Lannett securing two new substantial contracts, continued growth of established products, and decreases in R&D spending for the quarter.)
It'll run again this year. Company will have a market cap 3-4x what it is now once the XR Adderall revenue kicks in.
Courtesy of ama of what is coming up in the weeks ahead:
***** Within the next 7 weeks, ALL of the following will happen: *****
1. Elite Pharmaceuticals And SunGen Pharma File ANDA For An Antibiotic. (Product #4)
2. Elite Pharmaceuticals Enters into Strategic Marketing Alliance with ---------- For Codeine And Acetaminophen Combo. (Tylenol® with Codeine)
3. Elite Pharmaceuticals Announces Commercial Launch Of Generic Adderall XR With Marketing Partner Lannett Company.
4. Elite Pharmaceuticals And SunGen Pharma Receive FDA Approval For An Antibiotic. (Product #3 - Minor Amendment)
5. Elite Pharmaceuticals, Inc. Receives FDA Approval for Loxapine Capsules. (May not receive a PR for this. Will be updated on the CC.)
6. Elite Pharmaceuticals, Inc. Reports Record Revenues For The Third Quarter Of Fiscal Year 2020.
Also, earnings 4 or 5 weeks away.
I'll take your other prediction for what happens later this year too. ;)
We'll see with time. At under .10, I'd say this is a bargain for 2020.
If you haven't already, read this. Pretty much all you need to know in one article.
https://seekingalpha.com/article/4314697-not-all-strategic-transformations-are-elite-this-one-is?utm_medium=email&utm_source=seeking_alpha%3Fapp%3D1#alt2
The top message is literally WOW WOW WOW !!!!! SEEKINGALPHA !!!!!
Maybe you should start your "DD" there. But then again maybe that is asking too much.
I don't doubt he's looking at all available options as Elite will very soon be profitable. But I'm fairly certain raising the AS, then immediately doing a RS to uplist isn't on the table in 2020.
This. The fact that Nasrat has stopped talking about uplisting to the Nasdaq being on the agenda should tell you that he isn't planning on it in the near future. Definitely not happening this year.
Look at that volume. Primed for a run to a higher base.
2020 is going to be BUSY.
Nice volume to end the year. 2020 is going to be a busy and exciting.
So IPIX is looking for outside funding instead of diluting the stock more? I see the AS was recently raised from 300 to 600 million correct?
How much $ is expected to be needed to proceed?
What's the next piece of news (hopefully positive) that shareholders are looking forward to here? At the current market cap this seems like an attractive buy.
I think ELTP also trades on the Frankfurt Exchange...right? Maybe that's what he's referencing.
That method of thinking usually only applies to stocks that are down on the year. ELTP is up 26% YTD.
Where we currently sit at with an $80 million market cap, going to be making upwards of $60 million + next fiscal year, Elite is a tremendous buy at this price.
The ole' Lodrane days, who could forget. I first bought in a few months before that debacle. The company has come a long way since then. About time for the share price to take notice in 2020.
I believe 6 job openings is the most I've seen for us since I've been around.
Looks like a busy, filled start of the new year for us.
How about: Make America Concentrate Again 2020
I think 2 or 3 of those openings are new (meaning this month).
You can say that again. $80 million market cap, with a high likely hood of making $40 million in yearly revenues next year.
In due time the share price will increase when revenues arrive.
Not crickets; it's been stated numerous times that the $97 million antibiotic has been pushed back to March.
Yes, welcome back Aqua.
Middle of December too, just as Nasrat stated. Looks like little Elite is getting back on track and working out its plan.
Great news! Now for a fast launch in January or early February!
The stock was also .08 before it ran over 1000% in short fashion... wink wink.
Welcome, stick around.
Shareholder meeting is tomorrow.
So Elite should've launched the 2 opioids, then gotten sued and had to go under because they couldn't afford to fight the lawsuits? lol
As much as it sucks to say, Elite did the right thing here to not decimate the company.